Genomic and immune characteristics of HER2-mutated non-small-cell lung cancer and response to immune checkpoint inhibitor-based therapy.
Tu HY, Yin K, Zhao X, Ke EE, Wu SP, Li YS, Zheng MM, Liu SM, Xu CR, Sun YL, Lin JX, Bai XY, Zhang YC, Zhou Q, Yang JJ, Zhong WZ, Wang BC, Zhang XC, Zhu D, Yang L, Ou Q, Wu YL.
Tu HY, et al. Among authors: zhao x.
Mol Oncol. 2023 Aug;17(8):1581-1594. doi: 10.1002/1878-0261.13439. Epub 2023 Apr 29.
Mol Oncol. 2023.
PMID: 37078460
Free PMC article.